Identification of a series of tetrahydroisoquinoline derivatives as potential therapeutic agents for breast cancer

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 9, 2007, Pages 2581-2589

  Lin, Hsiang Ru ^a   Safo, Martin K ^b   Abraham, Donald J ^b  

^a NATIONAL KAOHSIUNG NORMAL UNIVERSITY   (Taiwan)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Agonist; Antagonist; Antiestrogen; Breast cancer; Estrogen receptor; Ligand binding domain; Progesterone receptor

Indexed keywords

4 (1,2 DIPHENYL 1 BUTENYL)CINNAMIC ACID; 4 HYDROXYTAMOXIFEN; ANILIDE; FULVESTRANT; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; PROGESTERONE RECEPTOR; RALOXIFENE; TAMOXIFEN; TETRAHYDROISOQUINOLINE DERIVATIVE; TRANSCRIPTION FACTOR AP 1;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CANCER; CELL PROLIFERATION; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; GENES, REPORTER; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR CONFORMATION; PROTEIN BINDING; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TETRAHYDROISOQUINOLINES;

EID: 33947727864     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.02.002     Document Type: Article

References (31)

1. Osborne C.K., Schiff R., Arpino G., Lee A.S., and Hilsenbeck V.G. Breast 14 (2005) 458
2. Macgregor J.I., and Jordan V.C. Pharmacol. Rev. 50 (1998) 151
3. Greene G.L., Gilna P., Waterfield M., Baker A., and Hort Y. Shine J. Science 231 (1986) 1150
4. Mosselman S., Polman J., and Dijkema R. FEBS Lett. 392 (1996) 49
5. Kumar V., Green S., Stack G., Berry M., Jin J.R., and Chambon P. Cell 51 (1987) 941
6. Kuiper G.G., Carlsson B., and Grandien K. Endocrinology 138 (1997) 863
7. McKenna N.J., Lanz R.B., and O'Malley B.W. Endocr. Rev. 20 (1999) 321
8. Katzenellenbogen B.S., Choi I., Delage-Mourroux R., Ediger T.R., Martini P.G.V., Montano M., Sun J., Weis K., and Katzenellenbogen J.A. J. Steroid Biochem. Mol. Biol. 74 (2000) 279
9. Perillo B., Sasso A., Abbondanza C., and Palumbo G. Mol. Cell Biol. 20 (2000) 2890
10. Augerean P., Miralles F., Cavailles V., Gaudelet C., Parker M., Rochefort H., and Wodak S. J. Mol. Endocrinol. 8 (1994) 693
11. Petz L.N., and Nardulli A.M. Mol. Endocrinol. 14 (2000) 972
12. Mueller M.D., Vigne J.L., Minchenko A., Lebovic D.I., Leitman D.C., and Taylor R.N. Proc. Natl. Acad. Sci. USA 97 (2000) 10972
13. Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J., Kushner P.J., and Scanlan T.S. Science 277 (1997) 1508
14. Moore M.R. Curr. Cancer Drug Targets 4 (2004) 183
15. Moore M.R., Conover J.L., and Franks K.M. Biochem. Biophys. Res. Commun. 277 (2000) 650
16. Gong Y., Anzai Y., Murphy L.C., Ballejo G., Holinka C.F., Gurpide E., and Murphy L. J. Cancer Res. 51 (1991) 5476
17. 3(1 mL, 10 mmol), compound 1g was synthesized following the above procedure for compound 1f.
18. 50 of test compound.
19. 5 cells in 2 ml maintained medium per well. Cells were allowed to attach to the bottom for 24 h incubation, then the seeding medium was removed and replaced by the experimental medium (phenol red-free DMEM supplemented with 5% charcoal-stripped fetal bovine serum and penicillin (100 U/ml)/Streptomycin (100 μg/ml). After further 24 h incubation, the test molecules dissolved in DMSO were added in the wells. The final concentration of DMSO in the culture medium did not exceed 0.1%. The culture was continued for 2 days. The final relative cell viability was estimated with Cell Titer proliferation assay kit (Promega, Madison, WI) by measuring the absorbance at 570 nm, which is directly proportional to the number of living cells in the culture. The testing was performed by following the manufacturer's protocol. Experiments were triplicated for each compound.
20. Perry R.R., Kang Y., and Greaves B. Ann. Surg. Oncol. 2 (1995) 238
21. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., and Greene G.L. Cell 95 (1998) 927
22. Pike A.C.W., Brzozowski A.M., Walton J., Hubbard R.E., Thorsell A.G., Li Y.L., Gustafsson J.A., and Carlquist M. Structure 9 (2001) 145
23. Wu Y.L., Yang X., Ren Z., McDonnell D.P., Norris J.D., Willson T.M., and Greene G.L. Mol. Cell 18 (2005) 413
24. Grese T., Cho S., Finley D.R., Godfrey A.G., Jones C.D., Lugar III C.W., Martin M.J., Matsumoto K., Pennington L.D., Winter M.A., Adrian M.D., Cole H.W., Magee D.E., Phillips D.L., Rowley E.R., Short L.L., Glasebrook A.L., and Bryant H.U. J. Med. Chem. 40 (1997) 146
25. Jordan V.C., Lieberman M.E., Cormier E., Koch R., Bagley J.R., and Ruenitz P.C. Mol. Pharm. 26 (1984) 272
26. Renaud J., Bischoff S.F., Buhl T., Floerscheim P., Fournier B., Halleux C., Kallen J., Keller H., Schlaeppi J.-M., and Stark W. J. Med. Chem. 46 (2003) 2945
27. Renaud J., Bischoff S.F., Buhl T., Floersheim P., Fournier B., Geiser M., Halleux C., Kallen J., Keller H., and Ramage P. J. Med. Chem. 48 (2005) 364
28. Nawaz Z., Stancel G.M., and Hyder S.M. Cancer Res. 59 (1999) 372
29. Williams S.P., and Sigler P.B. Nature 393 (1998) 392
30. Hillisch A., Von Langen J., Menzenbach B., Droescher P., Kauffman G., Schneider B., and Elger W. Steroids 68 (2003) 869
31. Coller J.K., Krebsfaenger N., Klein K., Endrizzi K., Wolbold R., Lang T., Nussler A., Neuhaus P., Zanger U.M., Eichelbaum M., and Murdter T.E. Br. J. Clin. Pharmacol. 54 (2002) 157